A preliminary study of intralesional, intralymph node, intravenous and intraperitoneal Corynebacterium parvum treatments in patients with advanced cancer.
Twenty-one patients with squamous cell carcinoma of oral cavity and/or cervical lymph node and four patients with soft tissue sarcomas were given intralesional (2-4 mg/m2) and intralymph node (2-4 mg/m2) C. parvum injections followed by 5 intravenous (2-4 mg/m2) C. parvum treatments and conventional therapies. Seven patients with Stage III ovarian carcinomas were given intraperitoneal (2-4 mg/m2) C. parvum injections followed by conventional therapies. The local and systemic effects of the C. parvum treatments were described and the anti-tumor effects were evaluated in this series of patients.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D005260:Female; D005334:Fever / Q000209:etiology; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007267:Injections; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008198:Lymph Nodes; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy*; D011425:Propionibacterium acnes / Q000276:immunology*; D012008:Recurrence; D012075:Remission, Spontaneous; D012509:Sarcoma / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy*